Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

被引：2
|
作者：
Spencer, Andrew [1 ]
Iversen, Katrine Fladeland [2 ]
Dhakal, Binod [3 ]
Creignou, Maria [4 ]
Chen, Jenny [5 ]
Hiemstra, Ida H. [6 ]
Bosgra, Sieto [6 ]
Badani, Avani [5 ]
Breij, Esther C. W. [6 ]
Brady, Lauren K. [5 ]
Sasser, A. Kate [5 ]
Malmberg, Anders [7 ]
Gregersen, Henrik [8 ]
Hansson, Markus [9 ]
Broijl, Annemiek [10 ]
Mateos, Maria-Victoria [11 ]
Plesner, Torben [2 ]
机构：
[1] Alfred Hosp, Melbourne, Vic, Australia
[2] Vejle Hosp, Vejle, Denmark
[3] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA
[4] Karolinska Univ Hosp, Dept Hematol, Huddinge, Sweden
[5] Genmab, Princeton, NJ USA
[6] Genmab, Utrecht, Netherlands
[7] Genmab, Copenhagen, Denmark
[8] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark
[9] Aalborg Univ Hosp, Aalborg, Denmark
[10] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands
[11] USAL CSIC, Hosp Univ Salamanca, IBSAL, IBMCC, Salamanca, Spain
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159116
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7320 / 7321
页数：2
相关论文
共 50 条
  • [1] GEN3014 (HexaBody ®-CD38) in Anti-CD38 Mab-Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial
    Grosicki, Sebastian
    Plesner, Torben
    Jurczak, Wojciech
    Radocha, Jakub
    Malek, Ehsan
    Hiemstra, Ida
    Brady, Lauren K.
    Chen, Jenny
    Gong, Nian
    Hindsberger, Charlotte
    Spencer, Andrew
    BLOOD, 2023, 142
  • [2] GEN3014 (HexaBody®-CD38) versus daratumumab in patients with relapsed/ refractory multiple myeloma: design of randomized head-to-head expansion cohort of phase 1/2 trial
    Grosicki, Sebastian
    Dhakal, Binod
    Malek, Ehsan
    Creignou, Maria
    Jurczak, Wojciech
    Broijl, Annemiek
    Iversen, Katrine Fladeland
    Gregersen, Henrik
    Radocha, Jakub
    Chen, Jenny
    Ogunkanmi, Adeleye
    Spencer, Andrew
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S62 - S63
  • [3] A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma - Preliminary Safety Data
    Gimsing, Peter
    Plesner, Torben
    Nahi, Hareth
    Lokhorst, Henk
    Valentin, Marie-Louise
    Lisby, Steen
    Richardson, Paul G.
    BLOOD, 2011, 118 (21) : 817 - 817
  • [4] Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study
    Plesner, Torben
    Lokhorst, Henk
    Gimsing, Peter
    Nahi, Hareth
    Lisby, Steen
    Richardson, Paul G.
    BLOOD, 2012, 120 (21)
  • [5] Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Alsina, Melissa
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (04) : 438 - 445
  • [6] Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma
    Lokhorst, Henk M.
    Plesner, Torben
    Gimsing, Peter
    Nahi, Hareth
    Minnema, Monique
    Lassen, Ulrik Niels
    Krejcik, Jakub
    Laubach, Jacob
    Lisby, Steen
    Basse, Linda
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - PRELIMINARY EFFICACY AND PHARMACOKINETICS DATA FROM A DOSE-ESCALATION PHASE I/II STUDY
    Lokhorst, H.
    Gimsing, P.
    Nahi, H.
    Richardson, P.
    Plesner, T.
    Lisby, S.
    HAEMATOLOGICA, 2012, 97 : 473 - 473
  • [8] Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
    Kazandjian, Dickran
    Quach, Hang
    Sia, Hanlon
    Ho, Phoebe Joy
    Spencer, Andrew
    Schroeder, Mark A.
    Dhakal, Binod
    Cochrane, Tara
    Zonder, Jeffrey A.
    Yi, Nancy
    Duchesne, Dominique
    Shah, Tejas
    Garton, Andrew
    Menon, Vinu
    Gn, Sunitha
    Sammicheli, Stefano
    Zhukovsky, Eugene
    Konto, Cyril
    Pacaud, Lida
    Tan, Peter
    BLOOD, 2023, 142
  • [9] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
    Shinsuke Iida
    Kenshi Suzuki
    Shigeru Kusumoto
    Masaki Ri
    Nobuhiro Tsukada
    Yu Abe
    Masayuki Aoki
    Mitsuo Inagaki
    International Journal of Hematology, 2017, 106 : 541 - 551
  • [10] OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY
    Hari, P.
    Shain, K. H.
    Voorhees, P.
    Gabrail, N.
    Abidi, M.
    Zonder, J.
    Boccia, R.
    Richardson, P. G.
    Neuman, L.
    Wong, H.
    Dixon, S.
    Prada, C. P.
    HAEMATOLOGICA, 2015, 100 : 254 - 255
12345